Although anti-angiogenic therapy targeting VEGF/VEGFR prolonged the overall survival of cancer patients, these drugs lead to untoward side effects, including lethal hemoptysis and intestinal perforation (Johnson et al., 2004; Jain et al., 2006). Here, KDR is linked to cancer.